This approach significantly improves T-cell proliferation, survival, and anti-tumor response (i.e., production of cytokines IFN-γ, TNF-α, and IL-6), particularly directed towards CD19+ and CD123+ hematological malignancies in vitro and in vivo. Here, CD19 is linked to hematologic disorder.